Literature DB >> 10382893

In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

The in-vitro activity of MK-0826, a new oral carbapenem, was compared with that of imipenem by broth microdilution susceptibility tests against 545 bacterial isolates. MK-0826 had significantly greater activity against Enterobacteriaceae and poorer activity against Pseudomonas aeruginosa and many gram-positive species. MK-0826 disc diffusion tests were also performed according to the NCCLS procedure and tentative interpretive criteria were determined for possible susceptible MIC breakpoints of < or = 4.0 and < or = 2.0 mg/L.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382893     DOI: 10.1093/jac/43.5.703

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

Authors:  H M Wexler; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.

Authors:  Glenn A Pankuch; Todd A Davies; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.

Authors:  D M Livermore; M W Carter; S Bagel; B Wiedemann; F Baquero; E Loza; H P Endtz; N van Den Braak; C J Fernandes; L Fernandes; N Frimodt-Moller; L S Rasmussen; H Giamarellou; E Giamarellos-Bourboulis; V Jarlier; J Nguyen; C E Nord; M J Struelens; C Nonhoff; J Turnidge; J Bell; R Zbinden; S Pfister; L Mixson; D L Shungu
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Authors:  Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

7.  Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Gregory L Kearns; Santiago Topelberg; Richard F Jacobs; Goutam C Mistry; Anup Majumdar; Yang Xu; John A Wagner; Chester J Kitchen; Michelle Groff; Gary Herman; Jeffrey L Blumer
Journal:  Pediatr Infect Dis J       Date:  2010-12       Impact factor: 2.129

Review 8.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

Authors:  C Betriu; A Sánchez; M L Palau; M Gómez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 10.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.